---
title: "Xizang Weixinkang Pharmaceutical's subsidiary, Amber Acetylated Gelatin Electrolyte Sodium Acetate Injection, has been approved for clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236177213.md"
description: "Xizang Weixinkang Pharmaceutical's wholly-owned subsidiary Baiyi Pharmaceutical recently received approval from the National Medical Products Administration to conduct clinical trials for Succinylated Gelatin Electrolyte Sodium Acetate Injection. This injection is based on the product of B.Braun Melsungen AG and is primarily used for the treatment of hypovolemia and shock, and can be used in conjunction with crystalloid solutions during extracorporeal circulation"
datetime: "2025-04-16T07:35:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236177213.md)
  - [en](https://longbridge.com/en/news/236177213.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236177213.md)
generator: "portal-rs"
---

# Xizang Weixinkang Pharmaceutical's subsidiary, Amber Acetylated Gelatin Electrolyte Sodium Acetate Injection, has been approved for clinical trials

According to the Zhitong Finance APP, Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as "Baiyi Pharmaceutical") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") for the Succinylated Gelatin Electrolytes Sodium Acetate Injection.

The Succinylated Gelatin Electrolytes Sodium Acetate Injection declared by Baiyi Pharmaceutical is developed based on the reference preparation Succinylated Gelatin Electrolytes Injection certified by B.Braun Melsungen AG. This product serves as a colloidal plasma volume substitute dissolved in isotonic electrolyte balanced solution, used for: 1. Treatment of relative or absolute hypovolemia and shock. 2. As a component of infusion fluid in conjunction with crystalloid solutions during the process of extracorporeal circulation (e.g., cardiopulmonary bypass)

### Related Stocks

- [603676.CN](https://longbridge.com/en/quote/603676.CN.md)

## Related News & Research

- [Bank of Communications proposes 2026 interim dividend of RMB 0.168 per share](https://longbridge.com/en/news/297303454.md)
- [Agricultural Bank of China Boosts Capital With RMB50 Billion Tier 2 Bond](https://longbridge.com/en/news/297305576.md)
- [CCB  1H26 Net Profit Up 4.62% YoY to RMB169.564B; Interim DPS Up 8.2% to RMB0.201](https://longbridge.com/en/news/297296140.md)
- [PSBC 1H26 Net Profit Up 4.6% to RMB51.5B; Interim DPS Hikes 8.1% to RMB0.133](https://longbridge.com/en/news/297298563.md)
- [China Minsheng Banking: Net profit declined 8.62% YoY despite revenue growth, with stable asset quality and capital](https://longbridge.com/en/news/297310507.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**